Drugs / SAR442257
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04401020 | Jul 2020 → Mar 2024 | cancer | Sanofi | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR442257 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04401020 ↗ |
| Route | Intravenous | “Route of administration: Intravenous infusion” NCT04401020 ↗ |